- Home
- GENK vs AKTX Comparison
GENK vs AKTX Comparison
Compare GENK & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- AKTX
- Stock Information
- Founded
- GENK 2011
- AKTX N/A
- Country
- GENK United States
- AKTX United States
- Employees
- GENK N/A
- AKTX N/A
- Industry
- GENK Restaurants
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- AKTX Health Care
- Exchange
- GENK Nasdaq
- AKTX Nasdaq
- Market Cap
- GENK 20.4M
- AKTX 37.2M
- IPO Year
- GENK 2023
- AKTX N/A
- Fundamental
- Price
- GENK $3.81
- AKTX $1.14
- Analyst Decision
- GENK Strong Buy
- AKTX
- Analyst Count
- GENK 2
- AKTX 0
- Target Price
- GENK $10.00
- AKTX N/A
- AVG Volume (30 Days)
- GENK 46.6K
- AKTX 26.9K
- Earning Date
- GENK 07-30-2025
- AKTX 08-18-2025
- Dividend Yield
- GENK 0.79%
- AKTX N/A
- EPS Growth
- GENK N/A
- AKTX N/A
- EPS
- GENK N/A
- AKTX N/A
- Revenue
- GENK $214,957,000.00
- AKTX N/A
- Revenue This Year
- GENK $17.79
- AKTX N/A
- Revenue Next Year
- GENK $15.87
- AKTX N/A
- P/E Ratio
- GENK N/A
- AKTX N/A
- Revenue Growth
- GENK 14.40
- AKTX N/A
- 52 Week Low
- GENK $3.16
- AKTX $0.85
- 52 Week High
- GENK $10.33
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- GENK 47.86
- AKTX 43.82
- Support Level
- GENK $3.72
- AKTX $1.10
- Resistance Level
- GENK $3.98
- AKTX $1.18
- Average True Range (ATR)
- GENK 0.22
- AKTX 0.05
- MACD
- GENK 0.02
- AKTX 0.00
- Stochastic Oscillator
- GENK 51.36
- AKTX 39.52
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.